Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 3,900 trials

CAR-T-Cell Treatment for High-Risk Mantle Cell Lymphoma

We are exploring a new CAR-T-cell therapy for patients with untreated high-risk Mantle Cell Lymphoma. The study compares this new approach to the standard treatment to see which is more effective and safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Prostate Cancer: 177Lu-PSMA-617 Treatment Study

We are evaluating whether adding 177Lu-PSMA-617 to standard treatment helps men with metastatic hormone-sensitive prostate cancer who are not responding well to current therapies. The goal is to see if this combination improves survival and disease control.

Hormone-sensitive Metastatic Prostate Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Advanced Colorectal Cancer: Cetuximab with Encorafenib and Binimetinib

We are studying a combination of three medications for patients with BRAF V600E mutated advanced colorectal cancer. The goal is to see if this treatment can help make surgery possible and improve overall health outcomes.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy

We are studying the long-term safety of eplontersen in adults with ATTR-CM. This trial will help us understand how well the treatment is tolerated over an extended period.

Transthyretin-Mediated Amyloid Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Prostate Cancer: ADT with Darolutamide

We are studying whether adding darolutamide to standard hormone therapy helps frail men with newly diagnosed metastatic prostate cancer live longer and feel better. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Prostate Cancer1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncology

Thromboprophylaxis for Advanced Germ Cell Tumors

We are studying a preventive treatment for patients with advanced germ cell tumors undergoing chemotherapy to see if it can help reduce the risk of blood clots. The trial also looks at the safety and cost-effectiveness of this treatment.

Testicular Germ Cell Tumor3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Pelizaeus-Merzbacher Disease: ION356 Treatment Study

We are evaluating the safety of ION356, a new treatment for Pelizaeus-Merzbacher Disease. This study will help us understand how well the treatment is tolerated when administered directly into the spinal fluid.

Pelizaeus-Merzbacher DiseaseSafety phase (I)No PlaceboInvestigational MedicinesNeurology

Cutaneous T-Cell Lymphoma: Mogamulizumab and Skin Radiation Therapy

We are studying a new treatment combining an antibody and skin radiation for patients with stage IB-IIB cutaneous T-cell lymphoma. The goal is to see if this approach improves survival and response rates compared to standard treatments.

Cutaneous T-cell LymphomaMycosis Fungoides and Sézary Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Cardiovascular Safety: BI 456906 for Overweight Individuals

We are testing a new medication for people with overweight or obesity and cardiovascular disease to see if it is as safe as a placebo. The study will also look at its effects on blood pressure and waist size.

Obesity>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Advanced Solid Tumors: INCA033890 Study

We are testing a new treatment called INCA033890 for individuals with advanced or metastatic solid tumors. This study aims to understand its safety and how it can be used in future treatments.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Advanced Breast Cancer: [177Lu]Lu-NeoB with Ribociclib and Fulvestrant

We are exploring a new treatment combination for patients with ER+, HER2-, and GRPR+ advanced breast cancer who have not responded to earlier therapies. The study aims to assess the safety and effectiveness of this approach.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)EndocrinologyOncology

Advanced Cutaneous Squamous Cell Carcinoma: INCB099280 Study

We are evaluating a new medication for people with advanced cutaneous squamous cell carcinoma to see how safe it is and if it may help improve their condition.

Recurrent and Metastatic Skin Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Acute Myeloid Leukemia: Gilteritinib vs. Midostaurin

We are studying whether gilteritinib works better than midostaurin for patients with AML or MDS with a FLT3 mutation. This trial looks at treatment effectiveness and safety during chemotherapy and maintenance therapy.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2)1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Methylmalonic Acidemia: mRNA-3705 Treatment Study

We are testing a new treatment, mRNA-3705, for individuals with isolated Methylmalonic Acidemia. The study aims to evaluate its safety and how well it lowers harmful acid levels in the blood.

Methylmalonic Aciduria>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Beta-Thalassemia: Luspatercept for Children

We are studying a new treatment called luspatercept for children with beta-thalassemia to find a safe dose and evaluate its effects on blood health. This trial includes both transfusion-dependent and non-transfusion-dependent participants.

Beta Thalassemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Atrial Fibrillation: Warfarin Study for Dialysis Patients

We are investigating the safety and effectiveness of warfarin in patients with atrial fibrillation who are on dialysis. This study aims to understand how this medication impacts their health.

Atrial FibrillationEnd-Stage Renal Disease>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyNephrology

Myelofibrosis and Essential Thrombocythemia: INCA033989 Study

We are evaluating the effects and safety of a new treatment called INCA033989 for individuals with myelofibrosis or essential thrombocythemia. This study aims to understand how well it works compared to current options.

Myeloproliferative Neoplasms>2 yearsSafety phase (I)HematologyOncology

Deucravacitinib for Pediatric Plaque Psoriasis

We are studying a new medication for children and teens with moderate to severe plaque psoriasis. The trial will help us understand how well it works and its safety compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyPediatrics

Eptinezumab for Pediatric Migraine Prevention

We are studying whether eptinezumab can help reduce the number of migraine days in children and teenagers with episodic migraines. This trial aims to find out if it is a safe and effective option for young patients.

MigraineConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Nipocalimab for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to 17 with generalized myasthenia gravis who are not getting enough benefit from their current therapy. The trial will help us learn about its safety and effectiveness.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPediatrics